Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is a specialty pharmaceutical company that develops and commercializes prescription drugs targeting rare neuromuscular and neurological diseases. Revenue is generated through net product sales of approved prescription therapies sold to patients, specialty pharmacies, and healthcare providers in the United States. The provided 10-K filing excerpt (filed 2026-02-25, accession 000119312526071525) does not contain sufficient detail to characterize market position, specific revenue figures, named competitors, segment breakdowns, founding history, or leadership with the specificity required for accurate attribution. Accordingly, those details are omitted.

Revenue model

Net product sales of prescription pharmaceuticals to specialty pharmacies and healthcare providers in the United States, as disclosed in the 10-K filed 2026-02-25.

Products and services

Prescription pharmaceutical products targeting rare neuromuscular and neurological diseases. Specific product names and segment revenue breakdowns are not supported by the provided filing excerpts.

Customers and end markets

Specialty pharmacies, healthcare providers, and patients with rare neuromuscular and neurological diseases in the United States. Customer concentration data not supported by the provided excerpts.

Value-chain role

Pharmaceutical developer and commercial-stage drug marketer focused on rare disease indications.

Geographic exposure

United States, based on the 10-K filed 2026-02-25. International exposure not supported by the provided excerpts.

Source: SEC 10-K, filed 2026-02-25

Industry: Pharmaceutical Preparations Peers: Akero Therapeutics, Inc. Celldex Therapeutics Inc Veracyte Inc Day One Biopharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. DYNAVAX TECHNOLOGIES CORP Ligand Pharmaceuticals Inc Syndax Pharmaceuticals Inc SpringWorks Therapeutics, Inc.